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The present study aimed to clarify the role of mast cells in colitis with relapse induced in Wistar rats by trinitrobenzenosulphonic
acid. Colitis induction increased the histamine concentration in the colon, which peaked on day 26. The number of mast cells,
probably immature, was ten times higher on day 8. Diﬀerent from animals infected with intestinal parasites, after colitis remission,
mast cells do not migrate to the spleen, showing that mast cell proliferation presents diﬀerent characteristics depending on
the inﬂammation stimuli. Treatment with sulfasalazine, doxantrazole, quercetin, or nedocromil did not increase the histamine
concentration or the mast cell number in the colon on day 26, thereby showing absence of degranulation of these cells. In
conclusion, although mast cell proliferation is associated with colitis, these cells and their mediators appear to play no clear role in
the colitis with relapses.
Copyright © 2009 Ana Carolina Luchini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
During mast cell degranulation, a variety of mediators are
released including histamine, prostaglandin D2, leukotriene
C4, platelet activating factor, heparin, and neutral proteases.
These cells may be involved in the etiology of inﬂammatory
diseases through their activation and degranulation [1],
including inﬂammatory bowel disease (IBD) and its main
clinical manifestations such as ulcerative colitis (UC) [2]
and Crohn’s disease (CD) [3]. IBD is characterized by
the development of chronic intestinal inﬂammation with
alternating periods of remission and active inﬂammatory
process. The etiology of IBD remains unknown, although it
isbelieved toinvolve severalinteractions withimmune, envi-
ronmental, and genetic factors [4]. Histamine the main mast
cell mediator—known to increase vascular permeability,
leukocyte inﬁltration, and smooth muscle contraction—has
been suggested as participating in intestinal inﬂammation
[5].Infact,rectalbiopsiesfrominﬂamedareasinIBDrelease
histamine spontaneously [6].
The mast cell participation in the intestinal mucosa
of patients with either ulcerative colitis or Crohn’s disease
is controversial; reports have shown mast cell numbers
being increased [7], decreased [8], or stable between active
IBD and control biopsies [9]. These discrepancies may
arise from diﬀerences in measurement techniques (tissue
ﬁxation, staining, cell counting) or due to the course of
the inﬂammatory process (active disease, remission, drug
treatment) [10]. Indeed, evaluation of mast cell function in
vivo is very complex because mast cells may release several
mediators endowed with opposite biological eﬀects [11]a n d
also participate in ﬁbrosis and the wound healing process
[11–13]. All these ﬁndings have led to the hypothesis that
mastcellsarenotonlyproinﬂammatoryeﬀectorcellsbutalso
aregulatorycomponentoftheimmunesystemwithanactive
involvement in tissue repair [12–14].
Incomparisonwithclinicalresearch,experimentalassays
using diﬀerent animal species may provide stable disease
models with less variation and, given an adequate number
of animals in the sample, appropriate statistical data analysis.2 Mediators of Inﬂammation
Since animal studies simulate the clinical symptoms and/or
pathogenesis, the data obtained from these studies are
useful for evaluation of disease etiology. Studies of mast-
cell-deﬁcient Ws/Ws rats have shown that mast cells are
not essential to the development of TNBS-induced colitis.
However, these prior studies used rats with TNBS-induced
colitis without the relapse, a common clinical manifestation
in the human IBD, and performed evaluations only on days
7 and 14 after colitis induction [15].
In this way, the present study aimed to determine if
mast cells and their mediators played any role in colitis
with relapse induced by TNBS in Wistar rats. Also, we
veriﬁed whether, during colitis remission, these mast cells
tend to migrate to the spleen, similarly to what occurs in
animals infected with bowel parasites [16, 17]. Moreover, we
employed inhibitors of mast cell secretion (nedocromil [18],
quercetin [19], and doxatranzole [20]) to verify whether the
colonmastcellsareactivatedinulcerativecolitiswithrelapse.
2.MaterialsandMethods
2.1. Animals. Speciﬁc pathogen-free (SPF) male Wistar rats
(180–200g) obtained from CEMIB-UNICAMP (Campinas,
SP, Brazil) were housed in markrolon cages (5 rats per cage)
and maintained in air-conditioned animal quarters with 12
hours light-dark cycle. Animals had free access to water
and food. The experimental protocol used was approved by
the Ethics Committee for Animal Experimentation of the
Institute of Biosciences, UNESP, Botucatu, SP, Brazil.
2.2. Drugs and Solutions. Doxatranzole (Merck) was dis-
solved in 5% dimethyl sulfoxide (DMSO). Nedocromil
(Sigma) and quercetin (Sigma) were dissolved in distilled
water and sulfasalazine (Sigma) in 1% methylcelulose. The
concentrations of DMSO and methylcellulose used do not
interfere with spontaneous histamine release.
2.3. Induction of Ulcerative Colitis with Relapse. Colitis was
induced by the method originally described by Morris et al.
[21]. Animals fasted overnight and were anaesthetized with
halothane. Under anesthesia, they received 10mg of TNBS
dissolved in 0.25mL 50% ethanol (v/v) by means of a teﬂon
cannulainserted8cmthroughtheanus.Ratsfromnoncolitic
groupreceived0.25mLofphosphatebuﬀeredsaline.After14
days, the animals received a second dose of 10 mg of TNBS
in an attempt to mimic the relapses common in human
IBD. After TNBS administration, rats were kept in a head-
downpositionuntiltheyrecoveredfromanesthesia,andthen
returned to their cage. Animal body weights and occurrence
of diarrhoea (as detected by perianal fur soiling) for each
group were recorded daily.
2.4. Experimental Design. Two experimental designs were
adopted in the present study. In the ﬁrst one, we assessed
the peak histamine concentration, the mast cell number,
the macroscopic features of colonic lesions, and the possible
mast cell migration to the spleen. Based on these preliminary
data, the second experiment was designed to evaluate the
Table 1: Criteria for assessment of macroscopic colonic damage.
Score Criteria
0 No damage
1 Hyperemia, no ulcers
2 Linear ulcer with no signiﬁcant
inﬂammation
3 Linear ulcer with inﬂammation
at one site
4 Two or more sites of
ulceration/inﬂammation
5
Two or more major sites of
ulceration and inﬂammation or
o n es i t eo f
ulceration/inﬂammation
extending >1cm along the length
of the colon
6–10
If damage covers >2cm along the
colon, the score is increased by 1
for each additional centimeter of
involvement
possible involvement of mast cells and histamine in the
TNBS-induced colitis relapse. In the second experiment,
the animals were treated with 25mg/Kg/day of sulfasalazine
(p.o.), 100mg/Kg/day of nedocromil (i.p.), 5mg/Kg/day of
doxantrazole (i.p.), or 10mg/Kg/day of quercetin (i.p.) for,
12 days after relapse induction. The treatments started 2
hours before the relapse induction and extended to the 26th
day after the initial colitis induction, which corresponds to
the peak histamine concentration. The parameters evaluated
were the total tissue histamine concentration, the mast cell
number, and the macroscopic features of colonic damage in
colitis-relapsed animals.
2.5. Macroscopic Analysis. Every two days two group of
animals (TNBS and saline group) were euthanized by an
overdose of halothane, the colonic segments were obtained
after laparotomy, and the eventual occurrence of adhesions
between the colon and adjacent organs was noted. They were
placed on an ice-cold plate, cleaned of fat and mesentery,
blotted on ﬁlter paper, weighed, and their lengths measured
under a constant load (2g). The colon was longitudinally
opened and scored for macroscopically visible damage on
a 0–10 scale (Table 1) by two observers unaware of the
treatment, according to the criteria described by Bell et al.
[22].
2.6. Tissue Histamine Concentration. The total histamine
amount in the colon was determined for each animal from
all the experimental groups. Tissue samples (approximately
30–100mg) to be used for evaluation of tissue histamine
concentration were weighed, the boiled in 3mL of 0.9%
saline for 10 minutes. The supernatants were trasferred to
clean tubes and stored at –20◦C until analysis. The samples
of the colon were analyzed, after the removal of proteins by
perchloric acid (2%) by the ﬂuorometric method of Shore etMediators of Inﬂammation 3
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Figure 1: Histamine concentration in colon and spleen of Wistar
ratswithcolitisinducedbyTNBS.Theresultsareexpressedasmean
± SEM (n = 6).
al. [23] using a modular automatic continuous ﬂow system
[24], with the omission of the extraction steps.
2.7. Microscopic Analysis. In the colitis relapse protocol,
representative whole gut specimens were taken from a region
of the inﬂamed colon corresponding to the adjacent segment
to assess the gross macroscopic damage and were ﬁxed in
Alfac solution (alcohol 68%, acetic acid 5%, and formalde-
hyde 10%) for 24 hours. Cross-sections were selected and
embedded in paraﬃn. Equivalent colonic segments were
also obtained from the saline group. Sections of 10μm
were obtained from diﬀerent levels and stained with 0.5%
toluidine blue (pH 0.5) [25]. The number of mucosal mast
cells in 10 randomly selected high-power ﬁelds (×100) was
counted, and the number per 10 ﬁelds was calculated. The
samples were analyzed by light microscopy.
2.8. Statistical Analysis. All results are expressed as mean
± S.E.M. Diﬀerences were tested using one way analysis
of variance (ANOVA) and post hoc least signiﬁcance tests
or by Student’s t-test for unpaired samples. Nonparametric
data (score) are expressed as median and interquartile range
(Q1–Q3) and were analyzed with the Mann-Whitney U test
or Kruskal-Wallis test. Diﬀerences between proportions were
analyzed by the Fisher’s exact test. Statistical signiﬁcance was
set at P<. 05.
3. Results
The histamine content proﬁle in the colon of TNBS-treated
Wistar rats did not change until the 10th day, when it started
increasing, peaking around the 26th day, and remaining
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Figure 2: Histamine concentration and mast cells number in
colon of Wistar rats with colitis induced by TNBS. The results are
expressed as mean ± SEM (n = 5–7). ∗P< . 05; ∗∗∗P< . 001 (by
Student’s t-test).
stable at least until day 40. The treatment did not change
the histamine content (from days 0 to 40) in the spleen
(Figure 1).
Although there was a signiﬁcant increase (about 10 fold)
in the mast cell number on days 8, 20, 26, and 28, the
increase in the histamine content after the TNBS treatment
was signiﬁcant only on the 26th and 28th days (Figure 2).
After the induction of the intestinal inﬂammatory process
by TNBS, the tissue damage (estimated by scores) increased,
already maximizing on the 2nd day, remaining high until
the 10th day when it started dropping, becoming almost
recoveredonthe14thday.Therelapseinduceddamagelevels
similar to those of the ﬁrst treatment, peaking around day
20 and recovering on day 30. Adhesions, diarrhea, and the
weight/length ratio presented similar behavior until the 14th
day. However, after the relapse only the diarrhea percentage4 Mediators of Inﬂammation
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Figure 3: (a) Histamine concentration and (b) mast cell number
in colon of Wistar rats with colitis induced by TNBS treated
with sulfasalazine (25mg/Kg/day) doxatranzole (5mg/Kg/day),
quercetine (10mg/Kg/day), or nedocromil (100mg/Kg/day) daily
from 14th until 26th days of induction of the colitis. The results
are expressed as mean ± SEM (n = 5–7). ∗P< . 05 versus
noncolitic group. #P< . 05; ##P< . 01 versus TNBS control group
(by ANOVA).
reached the high levels of the ﬁrst treatment; the percentage
of adhesions was about one fourth that of the ﬁrst treatment,
while the weight/length ratio showed very little alteration.
Body weight gain was reduced by TNBS colitis from day 2
to day 6, the moment from which the animals started to gain
weight again until the end of the experiment. However after
the relapse of the inﬂammatory process, the animals showed
loss of body weight again (Table 2). Statistical analyses show
signiﬁcant diﬀerences between noncolitic (saline) and colitic
(TNBS) groups in relation to tissue damage, body weight,
and colon weight/length ratio at days 8, 20, 26, and 28. For
adhesions and diarrhea, the diﬀerences were signiﬁcant at
days 8, 20, and 26 but not on day 28 (Table 3).
The colon histamine concentrations in colitic animals
treated with doxantrazol or quercetin rose to about the same
level as that of the TNBS control group, but were higher
than those of the sulfasalazine, nedocromil, and noncolitic
(saline) groups. There were no diﬀerences among the
groupstreatedwithsulfasalazine,nedocromil,andnoncolitic
(saline) (Figure 3(a)). The mast cell numbers in the colons
of all these groups follow the same proﬁle as the histamine
concentration when compared with the noncolitic (saline)
group (Figure 3(b)).
Pharmacological treatment of colitic rats with nedo-
cromil decreased the colon histamine concentration com-
pared with the TNBS control group (Figure 3(a)). Moreover,
the treatments with nedocromil and sulfasalazine decreased
the colon mast cell number compared with TNBS control
(Figure 3(b)).
Thetreatmentswithsulfasalazine,nedocromil,doxantra-
zole, and quercetin did not macroscopically attenuate the
reactivation of the inﬂammatory process in the colonic
tissue. There was no decrease in the macroscopic damage
score or in the colonic weight/length ratio when compared
with control colitic animals with relapse. In addition, no
signiﬁcant diﬀerences were found in the diarrhea incidence,
in focal adhesions to adjacent organs, or in body weight
(Table 4).
4. Discussion
Colitis induced in rats by the hapten TNBS has been
widely used in investigating the physiopathology of this
disease. However, this model has some limitations given
that once TNBS has been administered intracolonically the
inﬂammatory status resolves spontaneously with time until
the colonic mucosa is completely healed, which is not the
s i t u a t i o ni nh u m a nI B D[ 26]. Recently, G´ alvez et al. [26]a n d
Di Stasi et al. [27]r e p o r t e dam o d e lo fr e a c t i v a t e dc o l i t i s
similar to the protocol used in the present study. The second
intracolonic admininstration of TNBS eﬀectively resulted
in a reactivation of the colonic inﬂammatory response, as
evidenced by the alteration in the diﬀerent macroscopic and
general clinical parameters of inﬂammation. Intracolonic
administration of TNBS/ethanol as originally described [21]
elicited an inﬂammatory response in rats with characteristics
similar to those reported elsewhere: experimental animals
presented diarrhea [22] as well as anorexia and loss of weight
[23], while their colonic segments appeared grossly ulcerated
and inﬂamed, showing intense hyperemia and bowel wall
thickening [28].
Histamine has frequently been used as a biochemical
markerofmastcellnumbersintissues,because,otherthanin
therodentstomach,mastcellsrepresentthemajorperipheral
tissue repository of this amine [29]. Mast cell numbers are
strongly correlated with tissue histamine levels in a number
of diverse animal and human tissues, both in normal tissues
and in those undergoing ﬁbrosis or inﬂammation [29, 30].Mediators of Inﬂammation 5
Table 2: Damage score, changes in colonic weight, changes in body weight and incidence of adhesions and diarrhoea of colitic rats with
relapse induced by TNBS.
Days of treatment Damage score(a) (0–10) Colonic weight(b) (mg/cm) Body weight change (%) Adhesions (%) Diarrhoea (%)
0 0 (0–0) 67.2 ± 4.05 4.90 ± 0.50 0 0
2 7 (6–7.5) 129.0 ± 9.72 −7.20± 1.29 60 40
4 8 (6.5–9.5) 157.0 ± 17.35 −10.50± 0.52 80 100
6 7 (6–8) 196.8 ± 40.45 −3.56± 1.52 100 100
8 6 (5–7) 130.2 ± 9.38 15.98 ± 2.67 60 80
10 7 (3.5–8) 302.3 ± 63.78 24.02 ± 1.26 40 80
12 5 (1–5) 159.8 ± 16.09 23.78 ± 1.58 20 40
14 1 (1-1) 129.4 ± 6.01 26.48 ± 0.82 0 80
16 6 (6–6.5) 159.9 ± 18.21 10.52 ± 0.85 20 100
18 7 (6–8) 172.5 ± 17.37 14.68 ± 1.68 20 80
20 6 (5–6) 147.2 ± 9.59 24.95 ± 1.51 20 100
22 5.5 (5–6.5) 195.4 ± 17.77 29.12 ± 1.28 25 75
24 5 (5–6) 149.5 ± 15.01 30.02 ± 1.96 0 75
26 3 (2-2) 130.8 ± 4.97 35.85 ± 1.91 0 25
28 2 (2–3) 142.4 ± 3.76 50.02 ± 2.02 0 0
32 1 (1–4) 116.7 ± 6.89 51.58 ± 2.94 0 0
36 1 (0–1) 123.6 ± 5.89 56.44 ± 2.19 0 0
40 1 (0–1) 128.8 ± 3.23 62.85 ± 2.55 0 0
(a)Score data are expressed as median and interquartil interval. (b)Body weight changes is expressed as percentage change from the start of the experiment
(N = 6).
Table 3: Comparison between noncolitic and TNBS-control groups on damage score, colonic weight, body weight changes and incidence
of adhesions and diarrhoea.
Group (n = 5–11) and days
of treatment
Damage
score(a)
(0–10)
Colonic
weight(b)
(mg/cm)
Body weight
change (%)
Adhesion
(%)
Diarrhoea
(%)
Noncolitic (saline) (day 8th) 0 85.5 ± 2.77 42.00 ± 3.93 0 0
TNBS-control (day 8th) 6 (5–7)∗ 130.2 ± 9.38∗ 29.15 ± 2.23∗ 60∗ 80∗
Noncolitic (saline) (day
20th) 0 88.5 ± 2.42 41.70 ± 2.24 0 0
TNBS-control (day 20th) 6(5–6)∗ 147.2 ± 9.59∗ 34.18 ± 1.94∗ 20∗ 100∗
Noncolitic (saline)(day 26th) 0 101.2 ± 6.22 53.56 ± 2.37 0 0
TNBS-control (day 26th) 3(2-2)∗ 130.8 ± 4.97∗ 46.20 ± 1.45∗ 50∗ 50∗
Noncolitic (saline) (day
28th) 0 81.4 ± 1.98 57.55 ± 2.12 0 0
TNBS-control (day 28th) 2(2–3)∗ 142.4 ± 3.76∗ 51.61 ± 1.19∗ 00
(a)Score data are expressed as median and interquartil interval. (b)Colonic weight data are expressed as mean ± S.E.M. ∗Groups diﬀer signiﬁcantly from the
noncolitic group −P<. 05.
Table 4: Eﬀects of sulfasalazine, doxantrazole, quercetine, and nedocromil treatment on damage score, changes in colonic weight, body
weight, and incidence of diarrhea and adhesions in reactivated TNBS colitis.
Group (n = 5–7)
day 26th
Damage score(a) (0–10) Colonic weight(b) (mg/cm) Body weight change (%) Adhesion (%) Diarrhoea (%)
Noncolitic 0∗ 107.65 ± 6.80∗∗ 50.05 ± 2.45∗ 0∗ 0∗
TNBS-control 5(3–6) 145.56 ± 3.03 40.58 ± 1.15 58 28.5
Sulfasalazine 1(1–4) 142.52 ± 5.77 45.02 ± 2.93 20 14.0
Doxantrazole 3(1–3) 132.50 ± 4.22 40.45 ± 2.58 58 28.5
Quercetin 2(1–3) 138.08 ± 3.00 44.49 ± 2.09 40 14.0
Nedocromil 1(1–3) 134.23 ± 5.82 46.78 ± 1.98 40 14.0
(a)Score data are expressed as median and interquartil interval. (b)Colonic weight data are expressed as mean ± S.E.M. ∗Groups diﬀer signiﬁcantly from the
TNBS group −P< . 05. All groups diﬀer signiﬁcantly from the noncolitic (saline) group (P< . 01, not shown).6 Mediators of Inﬂammation
Inourcurrentstudy,thecolonichistamineconcentration
in colitic rats remained unchanged until 10 days after
colitis induction and then started rising to a peak on
day 26. Although the histamine concentration did not
change until 10 days after colitis induction, the mast cell
number increased both in the mucosal and submucosal
layers. Already on day 8 it was about 10 times higher,
and after that presented minor elevations until day 26.
This increase was certainly due to mast cell proliferation;
the absence of corresponding increase in the histamine
concentration is on account of the immaturity of these mast
cells, that consequently presented much less histamine in the
cytoplasmic granules [31].
This increase of mast cells until day 26 corroborated
previous ﬁndings obtained in the same model by Morris
et al. [21] who mentioned that mast cell numbers were
increased in inﬂamed tissues three and four weeks after
colitis induction; however, the role of these cells was not
speciﬁcally addressed. More recently, an increased mast cell
count in the 5–20 day period [32] and an elevated mast
cell protease-2 (RMPC-2) level at 3 weeks were reported in
colonic tissue taken from TNBS rats [15].
In spite of the intense mast cell proliferation observed
in the inﬂammatory process, these cells did not migrate
to the spleen during recovery from the disease as observed
in intestinal infection by Trichinella spiralis [17]. This fact
suggests that mast cell proliferation can show diﬀerent
characteristics depending on the type of inﬂammatory
process.
After inducing colitis by TNBS in Sprague Dawley rats,
Gelbamann and Barrett [5] also did not observe diﬀerences
in colonic histamine concentration until the end of the
ﬁrst week, but after 4 weeks this parameter had risen
sharply. It is interesting to note that these studies did
not employ relapse; however, after 28 days the histamine
concentrationintheirexperiments (16μg/g)washigherthan
in ours (10.5μg/g), suggesting that the relapse did not cause
additional proliferation of mast cells. In contrast, the relapse
caused extra stimuli that provoked tissue damage and higher
percentages of adhesions and diarrhea, even though not
much change could be seen in body weight and mass/length
ratio.
Xu et al. [32] reported that the mast cell number in the
colon of Sabra rats with TNBS-induced colitis was lower
during the ﬁrst ﬁve days after induction, suggesting mast
cell degranulation. This eﬀect was not observed in our
experiments since mast cells were more numerous on day 8
comparedwithnoncoliticsrats(salinegroup),suggestingthe
absence of mast cell degranulation.
Quercetin, doxantrazole, and nedocromil cause mast cell
stabilization with consequent inhibition of histamine release
[33]. In the present study we have shown that pretreatment
with either quercetin or doxantrazole did not change the
histamine concentration in the colon, suggesting absence of
histaminereleaseduringtheintestinalinﬂammatoryprocess;
otherwise, these drugs would cause an increase in the
histamine concentration. These treatments with quercetin or
doxantrazole suggest that mast cells are not activated in the
intestinal inﬂammatory process induced by TNBS. Similarly,
Gelbmann and Barrett [5] also did not observe histamine
concentration diﬀerences in the colon of colitic rats treated
with another antihistaminic agent, diphenhydramine, when
compared with TNBS-control rats.
Besides not increasing the histamine concentration,
nedocromil causes a decrease in histamine and mast cell
number, probably due to its inhibition of the proliferation
and diﬀerentiation of these cells [32]. Similarly, sulfasalazine
also causes reduction of mast cell number possibly due to its
well-known anti-inﬂammatory eﬀect [34].
In summary, we have shown that despite mast cells
being associated with the intestinal inﬂammatory process
as demonstrated by the elevations observed in mast cell
number and histamine concentration, it seems that these
cellsandmediators donot interferewithcolitis, at leastwhen
this inﬂammatory process was induced by administration of
TNBS. These results are in agreement with Chin and Barrett
[35] and Fukumoto et al. [15] who have demonstrated
that mast cells are not essential to the development of
TNBS-induced colitis in rats or mice. In addition, the
proliferated mast cells do not migrate to the spleen during
colitis remission, in contrast to what occurs in infection by
parasites.
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